At the completion of this activity, the participant will be able to:
1. Discuss the epidemiology and etiology of triple negative breast cancer (TNBC)
2. Review current guideline recommendations for treatment strategies in TNBC
3. Describe key literature regarding use of immunotherapy and PARP inhibitors in the setting of TNBC
4. Review mechanism of action, adverse effect, monitoring parameters, and key clinical pearls relating to PARP inhibitors and immunotherapy

Session date: 
Monday, October 11, 2021 - 12:00pm to 1:00pm
WPH Conference Center (Through Wintergarden Room)
Zoom Meeting
Meeting ID: 990 5197 6839; Passcode: 231203
United States
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Please login or register to take this course.